Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
15 Ottobre 2024 - 1:38PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES
EXCHANGE ACT OF 1934
October, 2024
Commission File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x
Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer
must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes
¨
No x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED
(Registrant) |
|
|
|
|
Date: October 14, 2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
K Randhir Singh |
|
|
Title: |
Company Secretary |
Exhibit 99.1
|
Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN : L85195TG1984PLC004507
Tel : +91 40 4900 2900
Fax : +91 40 4900 2999
Email : mail@drreddys.com
www.drreddys.com |
October 14, 2024
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: Disclosure
pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
This is in furtherance of our intimation dated
March 1, 2024, wherein we informed that Dr. Reddy’s Laboratories, Inc., wholly owned step down subsidiary of the Company, and Dr.
Reddy’s Laboratories Limited (“the Company”) were named as defendants in a complaint that was made public on February
29, 2024, in the United States District Court for the District of New Jersey. In continuation to the said complaint through amended complaints,
three additional groups of plaintiffs have sought to add DRL as a defendant in their already pending lawsuits previously consolidated
into the In re Revlimid antitrust action. The first such plaintiff is United Healthcare Services, Inc. (“United”). The second
such group of plaintiffs is composed of Cigna Corp., Humana Inc., Blue Cross Blue Shield Association, Health Care Service Corporation,
Blue Cross and Blue Shield of Florida, Inc., and Molina Healthcare, Inc. (together, the “Insurer Plaintiffs”). The third such
group of plaintiffs is composed of Jacksonville Police Officers and Fire Fighters Health Insurance Trust, Carpenters and Joiners Welfare
Fund, Teamsters Local 237 Welfare Fund and Teamsters Local 237 Retirees’ Benefit Fund, and Teamsters Western Region and New Jersey
Health Care Fund, who bring their claims on behalf of a purported class of end-payors of Revlimid® and generic equivalents (the “EPP
Plaintiffs”).
On June 6, 2024, the court issued an order on
pending motions to dismiss filed by other defendants, in which the court dismissed all claims at issue in that motion, including claims
challenging the litigation settlement agreements. The order allowed the relevant plaintiffs to file amended complaints. On August 5, 2024,
all Plaintiffs filed amended complaints, including the amended complaints filed by United, Insurer Plaintiffs, and EPP Plaintiffs, described
above, which sought to add DRL as a defendant in those actions for the first time. DRL and all other defendants to the In re Revlimid
antitrust action have filed motions to dismiss each of Plaintiffs’ lawsuits in their entirety. Those motions are pending. The Company
intends to vigorously defend its positions.
This is for your information and records.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR
Grafico Azioni Dr Reddys Laboratories (NYSE:RDY)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Dr Reddys Laboratories (NYSE:RDY)
Storico
Da Ott 2023 a Ott 2024